Clinical Trial Update: A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluated lorigerlimab in combination with docetaxel versus docetaxel alone in metastatic castration-resistant prostate cancer; the stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Lorigerlimab (lorigerlimab)

Snippet

Sponsor: MacroGenics | Conditions: Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Neoplasms | Phase 2 | Status: COMPLETED